Vanguard Personalized Indexing Management LLC Increases Stock Holdings in Abbott Laboratories $ABT

Key Points

• Vanguard Personalized Indexing Management LLC increased its holdings in Abbott Laboratories by 22.7% in Q2, now owning 278,752 shares worth approximately $37.9 million.
• Abbott Laboratories reported $1.26 EPS for the last quarter, meeting analyst expectations, with revenue reaching $11.14 billion, a 7.4% year-over-year increase.
• The company declared a quarterly dividend of $0.59 per share, with shares set to be paid on November 17th, representing an annual yield of 1.8%.

Vanguard Personalized Indexing Management LLC raised its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 22.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 278,752 shares of the healthcare product maker's stock after purchasing an additional 51,655 shares during the period. Abbott Laboratories comprises approximately 0.4% of Vanguard Personalized Indexing Management LLC's holdings, making the stock its 28th largest holding. Vanguard Personalized Indexing Management LLC's holdings in Abbott Laboratories were worth $37,936,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Edge Financial Advisors LLC raised its position in shares of Abbott Laboratories by 3.3% in the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock valued at $336,000 after purchasing an additional 81 shares in the last quarter. Avanza Fonder AB raised its position in shares of Abbott Laboratories by 0.4% in the 2nd quarter. Avanza Fonder AB now owns 168,401 shares of the healthcare product maker's stock valued at $22,904,000 after purchasing an additional 655 shares in the last quarter. Madrona Financial Services LLC raised its position in shares of Abbott Laboratories by 9.7% in the 2nd quarter. Madrona Financial Services LLC now owns 1,726 shares of the healthcare product maker's stock valued at $235,000 after purchasing an additional 152 shares in the last quarter. Janney Montgomery Scott LLC raised its position in shares of Abbott Laboratories by 12.4% in the 2nd quarter. Janney Montgomery Scott LLC now owns 669,868 shares of the healthcare product maker's stock valued at $91,109,000 after purchasing an additional 73,780 shares in the last quarter. Finally, SageView Advisory Group LLC increased its holdings in shares of Abbott Laboratories by 18.6% in the 1st quarter. SageView Advisory Group LLC now owns 18,294 shares of the healthcare product maker's stock valued at $2,427,000 after acquiring an additional 2,873 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Shares of ABT opened at $132.30 on Friday. The company has a market cap of $230.26 billion, a P/E ratio of 16.58, a PEG ratio of 2.51 and a beta of 0.69. The stock has a fifty day moving average price of $132.54 and a 200 day moving average price of $131.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts' consensus estimates of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm's revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories's payout ratio is 29.57%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.46% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ABT. Morgan Stanley boosted their price target on Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Raymond James Financial lowered their price target on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a report on Friday, July 18th. Mizuho boosted their price target on Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a report on Wednesday, July 16th. Weiss Ratings reiterated a "buy (b)" rating on shares of Abbott Laboratories in a report on Wednesday. Finally, BTIG Research lowered their price target on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $146.17.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.